Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
Conditions
Interventions
Pembrolizumab
Sacituzumab tirumotecan
+1 more
Locations
287
United States
Infirmary Cancer Care ( Site 0001)
Mobile, Alabama, United States
Ironwood Cancer & Research Centers-Research ( Site 0054)
Chandler, Arizona, United States
MemorialCare Orange Coast Medical Center ( Site 9501)
Fountain Valley, California, United States
Scripps Cancer Center ( Site 0052)
La Jolla, California, United States
Cancer and Blood Specialty Clinic ( Site 0008)
Los Alamitos, California, United States
Kaiser Permanente - Oakland ( Site 0079)
Oakland, California, United States
Start Date
June 24, 2024
Primary Completion Date
December 16, 2030
Completion Date
December 14, 2037
Last Updated
April 23, 2026
NCT06257264
NCT07525869
NCT05491226
NCT05660083
NCT05768932
NCT06767527
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions